DE602006017347D1 - COMPOSITION FOR THE TREATMENT OF CANCER FOR INTRATUMOROUS ADMINISTRATION AND ITS USE - Google Patents

COMPOSITION FOR THE TREATMENT OF CANCER FOR INTRATUMOROUS ADMINISTRATION AND ITS USE

Info

Publication number
DE602006017347D1
DE602006017347D1 DE602006017347T DE602006017347T DE602006017347D1 DE 602006017347 D1 DE602006017347 D1 DE 602006017347D1 DE 602006017347 T DE602006017347 T DE 602006017347T DE 602006017347 T DE602006017347 T DE 602006017347T DE 602006017347 D1 DE602006017347 D1 DE 602006017347D1
Authority
DE
Germany
Prior art keywords
administration
composition
cancer
intratumorous
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017347T
Other languages
German (de)
Inventor
Abdelilah Wakkach
Claudine Blin-Wakkach
David Momier
Georges Carle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602006017347D1 publication Critical patent/DE602006017347D1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention is related to a composition adapted for intra-tumoral administration of a subject suffering from cancer, whereby administration of said composition to said subject induces IMC differentiation by neutralizing a factor implicated in a DC differentiation defect and use thereof.
DE602006017347T 2005-04-15 2006-04-14 COMPOSITION FOR THE TREATMENT OF CANCER FOR INTRATUMOROUS ADMINISTRATION AND ITS USE Active DE602006017347D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05290842A EP1712241A1 (en) 2005-04-15 2005-04-15 Composition for treating cancer adapted for intra-tumoral administration and uses thereof
PCT/IB2006/001418 WO2006109188A2 (en) 2005-04-15 2006-04-14 Composition for treating cancer adapted for intra-tumoral asministration and uses thereof

Publications (1)

Publication Number Publication Date
DE602006017347D1 true DE602006017347D1 (en) 2010-11-18

Family

ID=35285458

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017347T Active DE602006017347D1 (en) 2005-04-15 2006-04-14 COMPOSITION FOR THE TREATMENT OF CANCER FOR INTRATUMOROUS ADMINISTRATION AND ITS USE

Country Status (6)

Country Link
US (1) US7888320B2 (en)
EP (2) EP1712241A1 (en)
AT (1) ATE483474T1 (en)
CA (1) CA2604542A1 (en)
DE (1) DE602006017347D1 (en)
WO (1) WO2006109188A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715115A2 (en) 2006-08-03 2013-06-04 Vaccinex Inc isolated monoclonal antibody, isolated nucleic acid molecule, expression vector, host cell, methods for treating a disease, and for producing an isolated monoclonal antibody, use of isolated monoclonal antibody, and, pharmaceutical composition
US9907819B2 (en) * 2012-06-27 2018-03-06 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors
SG11201510552WA (en) * 2012-06-27 2016-01-28 Hasumi Internat Res Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3140757B2 (en) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート Packaging defective HIV provirus, cell lines and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
KR920701246A (en) 1989-07-14 1992-08-11 스타이나 브이. 칸스타드 Antagonist of GM-CSF derived from carboxyl terminus
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
SK8396A3 (en) 1993-07-26 1997-03-05 Schering Corp Antagonists and agonists of human interleukin-10
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
PL336523A1 (en) 1997-04-28 2000-07-03 Rhone Poulenc Rorer Sa Intraneoplastic delivery of an angiogenesis antagonist by means of adenoviruses in order to treat neoplasms
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
BR9912053A (en) * 1998-07-13 2001-04-03 Univ Texas Cancer treatment processes using therapeutic conjugates that bind to aminophospholipids
CN101073668A (en) * 1999-04-28 2007-11-21 德克萨斯大学董事会 Antibody compositions for selectively inhibiting vegf
PT1092779E (en) 1999-10-11 2010-01-19 Pasteur Institut Lentiviral vectors for the preparation of immunotherapeutical compositions
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal

Also Published As

Publication number Publication date
ATE483474T1 (en) 2010-10-15
EP1871415A2 (en) 2008-01-02
WO2006109188A2 (en) 2006-10-19
EP1871415B1 (en) 2010-10-06
US20090148452A1 (en) 2009-06-11
US7888320B2 (en) 2011-02-15
CA2604542A1 (en) 2006-10-19
WO2006109188A3 (en) 2007-05-31
EP1712241A1 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
DE602005022113D1 (en) PHENYL) METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRICAL DISEASES
ATE493407T1 (en) 3-(HETEROARYLOXY)-2-ALKYL-1- AZABICYCLOALKYL DERIVATIVES AS ALPHA.7 NEGATIVE LIGANDS FOR THE TREATMENT OF CNS DISEASES
ATE542823T1 (en) 4,5-DIHYDRO-Ä1,2,4ÜTRIAZOLOÄ4,3-FÜPTERIDINE AS A PLK1 PROTEIN KINASE INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES
DE602006018057D1 (en) SUBSTITUTED CHINOLINES AND USE PROCESS
DE602006019838D1 (en) PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE FOR THE TREATMENT OF MENTAL DISEASES
ATE482939T1 (en) NEW ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR THE TREATMENT OF MAMMAL INFECTIONS
ATE519488T1 (en) AMINOPYRAZINE ANALOGUE FOR THE TREATMENT OF GLAUCOMA AND OTHER DISEASES CAUSED BY RHO-KINASE
ATE493986T1 (en) DIARYLUREAS FOR THE TREATMENT OF PULMONARY HYPERTENSION
CY1109985T1 (en) PROTESTOUS SUSPENSIONS AND METHODS OF USING THESE
ATE494890T1 (en) ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF ADDICTION DISORDERS
DE602006010243D1 (en) 4- (phenylamino) -6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative disorders
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
DE602005023172D1 (en) HYDANTINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
ATE429218T1 (en) PINOLENEIC ACID FOR THE TREATMENT OF OBESITY
ATE521365T1 (en) KININ ANTAGONISTS FOR THE TREATMENT OF BLADDER DISORDER
ATE456955T1 (en) USE OF CYCLODEXTRIN TO TREAT AND PREVENT BRONCHIAL INFLAMMATORY DISEASE
DE602007011906D1 (en) TETRAHYDROPYRIDOTHIA PYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
DE602006017574D1 (en) USE AS PROTEIN KINASE INHIBITORS BENZIMIDAZOLE
ATE446754T1 (en) COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA AND/OR GLUCO-REGULATORY DISORDERS
DE602005010821D1 (en) CONDENSED HETEROYRAL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS
NO20075368L (en) Anti-inflammatory modalities
ATE496913T1 (en) NEW, LONG-ACTING BETAMIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
ATE512133T1 (en) 1H-PYRROLE-2-CARBONIC ACID AMIDES AND IMIDAZOLE-5-CARBONIC ACID AMIDES AND THEIR USE AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER
DE602006003094D1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCHINOLINE DERIVATIVES FOR THE TREATMENT OF BARRENESS
DE602004021435D1 (en) INJECTABLE COMPOSITION FOR THE TREATMENT OF CANCER